River Road Asset Management LLC Sells 179,291 Shares of Pfizer Inc. (NYSE:PFE)

River Road Asset Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 20.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 695,696 shares of the biopharmaceutical company’s stock after selling 179,291 shares during the quarter. River Road Asset Management LLC’s holdings in Pfizer were worth $20,029,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Front Street Capital Management Inc. increased its position in Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 215 shares in the last quarter. Castleview Partners LLC increased its holdings in Pfizer by 2.4% in the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 287 shares in the last quarter. United Bank raised its stake in Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after acquiring an additional 290 shares during the period. Compton Capital Management Inc. RI lifted its holdings in Pfizer by 0.5% during the first quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock valued at $3,308,000 after purchasing an additional 300 shares in the last quarter. Finally, GHP Investment Advisors Inc. boosted its position in shares of Pfizer by 2.4% in the fourth quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 307 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Trading Down 1.1 %

PFE stock opened at $25.42 on Thursday. The firm has a fifty day moving average price of $27.19 and a 200 day moving average price of $28.76. Pfizer Inc. has a fifty-two week low of $25.26 and a fifty-two week high of $40.56. The firm has a market cap of $143.94 billion, a PE ratio of 70.57, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter last year, the business earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.